CD20 antibodies with increased FC receptor binding affinity and effector function
Details for Australian Patent Application No. 2004287643 (hide)
International Classifications
Event Publications
1 June 2006 PCT application entered the National Phase
PCT publication WO2005/044859 Priority application(s): WO2005/044859
10 November 2011 Alteration of Name
The name of the applicant has been altered to Roche GlycArt AG 2005
17 November 2011 Application Accepted
Published as AU-B-2004287643
9 February 2012 Application for Amendment
The nature of the amendment is as shown in the statement(s) filed 12 Dec 2011. Address for service in Australia - Davies Collison Cave Level 14 255 Elizabeth Street Sydney NSW 2000 2005
31 May 2012 Amendment Made
The nature of the amendment is as shown in the statement(s) filed 12 Dec 2011 2005
7 June 2012 Standard Patent Sealed
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
2004287645-Variants of human glycoprotein hormone alpha chain: compositions and uses thereof
2004287642-Allosteric modulators of metabotropic glutamate receptors
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
![](/images/main/3dbox_small.png)
- Editable Word format reports
- For IP Professionals
- Multiuser